ERP144942 Track Settings
 
Validation of differentially methylated DNA regions in colorectal precancerous lesions. [Colon]   (Human methylome studies)

This track is part of a parent called 'Human methylome studies'. To show other tracks of this parent, go to the Human methylome studies configuration page.

Maximum display mode:       Reset to defaults   

Select views (help):
CpG reads ▾       CpG methylation ▾       AMR       PMD       HMR      
Select subtracks by views and experiment:
 All views CpG reads  CpG methylation  AMR  PMD  HMR 
experiment
ERX10332595 
ERX10332596 
ERX10332606 
ERX10332608 
ERX10332609 
ERX10332612 
ERX10332625 
ERX10332636 
ERX10332647 
ERX10332658 
ERX10332669 
ERX10332680 
ERX10332688 
ERX10332691 
ERX10332702 
ERX10332706 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 ERX10332595  HMR  Colon / ERX10332595 (HMR)   schema 
hide
 ERX10332595  CpG methylation  Colon / ERX10332595 (CpG methylation)   schema 
hide
 ERX10332596  HMR  Colon / ERX10332596 (HMR)   schema 
hide
 ERX10332596  CpG methylation  Colon / ERX10332596 (CpG methylation)   schema 
hide
 ERX10332606  HMR  Colon / ERX10332606 (HMR)   schema 
hide
 ERX10332606  CpG methylation  Colon / ERX10332606 (CpG methylation)   schema 
hide
 ERX10332608  HMR  Colon / ERX10332608 (HMR)   schema 
hide
 ERX10332608  CpG methylation  Colon / ERX10332608 (CpG methylation)   schema 
hide
 ERX10332609  HMR  Colon / ERX10332609 (HMR)   schema 
hide
 ERX10332609  CpG methylation  Colon / ERX10332609 (CpG methylation)   schema 
hide
 ERX10332612  HMR  Colon / ERX10332612 (HMR)   schema 
hide
 ERX10332612  CpG methylation  Colon / ERX10332612 (CpG methylation)   schema 
hide
 ERX10332625  HMR  Colon / ERX10332625 (HMR)   schema 
hide
 ERX10332625  CpG methylation  Colon / ERX10332625 (CpG methylation)   schema 
hide
 ERX10332636  HMR  Colon / ERX10332636 (HMR)   schema 
hide
 ERX10332636  CpG methylation  Colon / ERX10332636 (CpG methylation)   schema 
hide
 ERX10332647  HMR  Colon / ERX10332647 (HMR)   schema 
hide
 ERX10332647  CpG methylation  Colon / ERX10332647 (CpG methylation)   schema 
hide
 ERX10332658  HMR  Colon / ERX10332658 (HMR)   schema 
hide
 ERX10332658  CpG methylation  Colon / ERX10332658 (CpG methylation)   schema 
hide
 ERX10332669  HMR  Colon / ERX10332669 (HMR)   schema 
hide
 ERX10332669  CpG methylation  Colon / ERX10332669 (CpG methylation)   schema 
hide
 ERX10332688  HMR  Colon / ERX10332688 (HMR)   schema 
hide
 ERX10332680  CpG methylation  Colon / ERX10332680 (CpG methylation)   schema 
hide
 ERX10332691  HMR  Colon / ERX10332691 (HMR)   schema 
hide
 ERX10332688  CpG methylation  Colon / ERX10332688 (CpG methylation)   schema 
hide
 ERX10332706  HMR  Colon / ERX10332706 (HMR)   schema 
hide
 ERX10332691  CpG methylation  Colon / ERX10332691 (CpG methylation)   schema 
hide
 ERX10332702  CpG methylation  Colon / ERX10332702 (CpG methylation)   schema 
hide
 ERX10332706  CpG methylation  Colon / ERX10332706 (CpG methylation)   schema 
    

Study title: Validation of differentially methylated DNA regions in colorectal precancerous lesions.
SRA: ERP144942
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
ERX10332595 Colon 0.526 4.6 31416 2198.0 1838 1048.5 199 46224.2 0.983 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332596 Colon 0.528 5.5 31616 1654.5 3872 1005.5 324 40418.1 0.983 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332606 Colon 0.534 6.6 28874 1915.0 9096 1144.9 124 48950.1 0.984 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332608 Colon 0.480 5.8 31450 1610.1 5309 990.2 369 48426.2 0.984 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332609 Colon 0.553 7.0 27936 1957.6 10586 1203.0 190 38583.8 0.984 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332612 Colon 0.512 4.2 30744 1770.8 2845 962.5 286 56455.4 0.983 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332625 Colon 0.572 6.0 35863 1534.0 3348 1009.9 581 29776.5 0.983 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332636 Colon 0.547 3.5 27878 3664.0 1528 1140.7 880 1269586.1 0.983 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332647 Colon 0.538 3.8 31474 1669.5 1950 960.5 350 47413.2 0.984 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332658 Colon 0.500 5.6 31793 1787.5 4819 1000.8 173 59947.1 0.984 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332669 Colon 0.502 4.9 32496 1725.5 3672 978.7 273 58547.1 0.983 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332680 Colon 0.547 4.2 27091 4625.9 2468 1188.8 968 1182680.1 0.983 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332688 Colon 0.528 3.5 29727 2057.1 2964 1018.7 108 100231.4 0.983 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332691 Colon 0.544 6.1 32072 1746.3 5629 1082.9 382 34464.5 0.983 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332702 Colon 0.487 6.3 18620 14270.6 2574 1163.1 1527 848773.4 0.983 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.
ERX10332706 Colon 0.554 3.8 28784 1960.8 4917 1145.6 103 110257.8 0.984 Illumina NovaSeq 6000 paired end sequencing; Validation of differentially methylated DNA regions in colorectal precancerous lesions.

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.